Phathom Pharmaceuticals, INC Schedule 13G passive stakes

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 4.2% of Phathom Pharmaceuticals, Inc. common stock.

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, reported a 5.3% beneficial ownership stake in Phathom Pharmaceuticals, Inc.

Millennium Management and affiliated entities have updated their passive beneficial ownership in Phathom Pharmaceuticals, Inc., reporting a collective stake of 2.7% as of December 31, 2025.

Millennium Management and affiliated entities have increased their beneficial ownership in Phathom Pharmaceuticals, Inc. to 7.1%.

Carlyle Group and its affiliates reported their beneficial ownership in Phathom Pharmaceuticals, Inc. has fallen to 4.9% due to dilution from the issuer's stock issuances.

Millennium Management LLC and affiliated entities have disclosed a 5.9% beneficial ownership stake in Phathom Pharmaceuticals, Inc. through a Schedule 13G filing.

Millennium Management LLC and affiliates have disclosed a 5.3% passive ownership stake in Phathom Pharmaceuticals, Inc. common stock.

Jennison Associates LLC has filed an amended Schedule 13G, indicating they no longer hold any beneficial ownership in Phathom Pharmaceuticals Inc. as of May 31, 2025.

Prudential Financial, Inc. has filed an amended Schedule 13G, disclosing a passive beneficial ownership of 2,630 common shares, representing 0.0% of Phathom Pharmaceuticals, Inc.

Jennison Associates LLC has filed an amended Schedule 13G for Phathom Pharmaceuticals Inc., indicating a 0% beneficial ownership of the company's common stock as of April 30, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a passive beneficial ownership of 4.6% in Phathom Pharmaceuticals, Inc. as of March 31, 2025.